SynBiotic SE (ETR:SBX)
2.675
+0.035 (1.33%)
Oct 30, 2025, 1:07 PM CET
SynBiotic SE Revenue
In the year 2023, SynBiotic SE had annual revenue of 3.86M EUR, down -52.71%. SynBiotic SE had revenue of 3.55M in the quarter ending June 30, 2024.
Revenue
3.86M
Revenue Growth
-52.71%
P/S Ratio
5.17
Revenue / Employee
70.21K
Employees
55
Market Cap
19.95M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3.86M | -4.30M | -52.71% |
| Dec 31, 2022 | 8.17M | -898.09K | -9.91% |
| Dec 31, 2021 | 9.06M | 3.59M | 65.63% |
| Dec 31, 2020 | 5.47M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 46.17B |
| Siemens Healthineers AG | 23.38B |
| Fresenius SE & Co. KGaA | 22.28B |
| Merck KGaA | 21.22B |
| Fresenius Medical Care AG | 19.52B |
| Sartorius Aktiengesellschaft | 3.52B |
| Redcare Pharmacy NV | 2.82B |
| Fielmann Group AG | 2.40B |
SynBiotic SE News
- 9 days ago - EQS-News: SYNBIOTIC welcomes Green Party’s proposal for the Industrial Hemp Liberalization Act and calls for objectivity in the medical cannabis debate - Wallstreet:Online
- 10 days ago - Temporary headwinds from regulatory uncertainty; chg. est. - Wallstreet:Online
- 4 weeks ago - EQS-News: Positive Outlook: Cannabis Legalization Review and Trump’s Endorsement Send Encouraging Signals - Wallstreet:Online
- 2 months ago - EQS-News: Across the pond: SYNBIOTIC attracts international investors with established intercontinental networks - Wallstreet:Online
- 3 months ago - SynBiotic Eyes Triple Revenue by 2027 in Cannabis & Hemp Markets - Wallstreet:Online
- 6 months ago - EQS-DD: SYNBIOTIC SE: HempConsult GmbH, Lending (free of charge) of 50,000 shares as part of a securities lending programme. - Wallstreet:Online
- 8 months ago - EQS-News: Quo vadis legalisation: SYNBIOTIC and GOC NEXUS at the International Cannabis Business Conference (ICBC) in Berlin - Wallstreet:Online
- 10 months ago - EQS-News: SYNBIOTIC with four new investments in 2024: Further acquisitions in sight for 2025 - Wallstreet:Online